Research
Hormonal
Obesity and high glucose/high lipid environments induce 'APN resistance' by disrupting the AdipoR1/caveolin signalosome, thereby diminishing the cardioprotective effects of adiponectin.
If you have diabetes or obesity, your body may become resistant to the protective effects of adiponectin. This 'APN resistance' means that simply having the hormone isn't enough; the signaling pathway is broken. Addressing the underlying metabolic stress (glucose/lipid control) is necessary to restore this protective signaling.
GoodRefutesHIGH confidence
Treatment with high glucose/high lipid disrupts the AdipoR1/Cav signalosome, leading to APN resistance. The diabetic condition itself may cause cardiac APN resistance, diminishing the cardioprotective effects of APN.
Why this rating
Strong experimental evidence from cell culture and animal models showing signalosome disruption.
Source
Role of Adipokines in Cardiovascular Disease
Wayne Bond Lau et al. · Circulation Journal · 2017
DOI 10.1253/circj.cj-17-0458
narrative_reviewCited 176×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adiponectin (APN) exerts cardiovascular protective effects by activating AMPK and eNOS pathways, promoting endothelial cell survival, reducing inflammation, and inhibiting atherosclerosis progression.Good
- CTRP9 is a potent cardioprotective adipokine that attenuates acute ischemia/reperfusion injury and mitigates pathologic ventricular remodeling post-MI, primarily via PKA-dependent pathways.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →